๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Perspective slow-release sodium fluoride in osteoporosis

โœ Scribed by Charles Y. C. Pak; Joseph E. Zerwekh; Peter P. Antich; Norman H. Bell; Frederick R. Singer

Publisher
American Society for Bone and Mineral Research
Year
2009
Tongue
English
Weight
342 KB
Volume
11
Category
Article
ISSN
0884-0431

No coin nor oath required. For personal study only.

โœฆ Synopsis

N Now hiiii I< 17. 1995. the FDA Endocrinologic and O M C t , 'I I mlic Drugs Advisory Committee unanimously rccomnicndcd approval of slow-release sodium fluoride (SR-NaF) for the treatment o f postmenopausal osteoporosis. 'l'hc oljcctivc o f this editorial is t o highlight the presentations before The Advisory Committee with the hope that it will help t o prevent misunderstanding or confusion about the product.

๐Ÿ“œ SIMILAR VOLUMES

Comparison of nonrandomized trials with
Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis
โœ Dr. Charles Y.C. Pak; Khashayar Sakhaee; Norman H. Bell; Angelo Licata; Conrad J ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› American Society for Bone and Mineral Research ๐ŸŒ English โš– 786 KB

The results of slow-release sodium fluoride (SR-NaF) treatment in two nonrandomized trials involving 65 patients with postmenopausal osteoporosis from the primary site and 121 patients from collaborative sites were compared with those obtained from 54 treated patients and 56 patients taking placebo